Business Description
Founded in 2009 and based in Tianjin, China, CanSino Biologics researches, produces, and sells vaccines across a range of serious infectious diseases. Its portfolio includes approved vaccines for COVID-19 and Ebola, along with several candidates in clinical trials targeting pneumonia, meningitis, whooping cough, and tuberculosis. The company is also advancing a number of earlier-stage vaccines addressing conditions such as polio, shingles, and tetanus.
